Hims & Hers Health, Inc. (NYSE:HIMS) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Analysts have a “Hold” consensus on Hims & Hers Health, with 11 hold, four buy and one sell rating among 16 brokerages. The average 12-month price target is $31.43.
• The stock opened at $31.58 and is up 6.5%, but the company recently reported an adjusted loss of $0.40 per share, missing expectations for $0.04 in earnings; revenue of $608.1 million also fell short of estimates.
• Insiders sold 83,126 shares worth approximately $2.7 million over the past three months, while institutional investors own 63.52% of the company and Vanguard increased its stake by 7.2% in the fourth quarter.

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) have earned an average recommendation of "Hold" from the sixteen brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $31.4333.

HIMS has been the subject of a number of recent analyst reports. Truist Financial boosted their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a research note on Friday, July 24th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a $25.00 price objective on shares of Hims & Hers Health in a report on Tuesday, May 5th. Weiss Ratings cut shares of Hims & Hers Health from a "hold (c)" rating to a "sell (d)" rating in a research report on Tuesday, May 12th. JPMorgan Chase & Co. dropped their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 12th. Finally, Wall Street Zen lowered shares of Hims & Hers Health from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th.

Hims & Hers Health Stock Up 6.5%

Shares of NYSE HIMS opened at $31.58 on Friday. Hims & Hers Health has a 1 year low of $13.74 and a 1 year high of $65.30. The firm has a 50-day simple moving average of $31.86 and a two-hundred day simple moving average of $26.10. The company has a market cap of $7.31 billion, a P/E ratio of -350.89, a PEG ratio of 83.47 and a beta of 2.40. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of $0.04 by ($0.44). The business had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The company's quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.20 EPS. Research analysts anticipate that Hims & Hers Health will post 0.03 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 18,197 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $34.03, for a total transaction of $619,243.91. Following the transaction, the chief financial officer owned 284,321 shares of the company's stock, valued at approximately $9,675,443.63. This represents a 6.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of the firm's stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total value of $441,850.50. Following the transaction, the chief operating officer owned 432,124 shares in the company, valued at approximately $13,611,906. This represents a 3.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 83,126 shares of company stock worth $2,711,339 over the last three months. Corporate insiders own 11.76% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in shares of Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company's stock worth $679,456,000 after buying an additional 1,407,651 shares during the last quarter. Munich Reinsurance Co Stock Corp in Munich acquired a new stake in Hims & Hers Health in the fourth quarter worth about $11,187,000. Cunning Capital Partners LP purchased a new stake in shares of Hims & Hers Health during the fourth quarter worth about $1,110,000. Virtu Financial LLC purchased a new stake in shares of Hims & Hers Health during the fourth quarter worth about $1,937,000. Finally, Norges Bank acquired a new position in shares of Hims & Hers Health during the fourth quarter valued at about $62,153,000. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source